Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie současného podávání zkoumané vakcíny proti živému atenuovanému respiračnímu syncyciálnímu viru u kojenců a batolat (CORAL)

15. září 2026 aktualizováno: Sanofi Pasteur, a Sanofi Company

Randomizovaná, jednoduše zaslepená, placebem kontrolovaná, multicentrická studie fáze III k vyhodnocení neinterference současného podávání rutinních dětských vakcín na protilátkovou odpověď zkoumané vakcíny s živým atenuovaným respiračním syncyciálním virem (RSV) u zdravých kojenců a Batolata (CORAL)

This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12 months of age (Cohort 2). The primary objective of the study will be to assess non-inferiority of the RSV infant and toddler (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine [Vaxelis® or Pentacel® and Recombivax HB®] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.

Přehled studie

Postavení

Ukončeno

Podmínky

Intervence / Léčba

Detailní popis

The study duration is approximately 9 months for each participant.

  • Cohort 1: Visits at 6, 7, and 8 and 9 months of age for both groups with visit at 10 months of age for Group 2 only
  • Cohort 2: Visits at 12, 13, 14 and 15 months of age for both groups with visit at 16 months of age for Group 4 only
  • Routine pediatric vaccines (authorized auxiliary medicinal products (AxMP) will be administered at 6 months in Cohort 1 and 12 months of age in Cohort 2, as per Advisory Committee on Immunization Practice (ACIP) or local country recommendations.

Typ studie

Intervenční

Zápis (Aktuální)

2226

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Mexico City, Mexiko, 06760
        • Investigational Site Number : 4840004
    • Mexico City
      • Mexico City, Mexico City, Mexiko, 04530
        • Investigational Site Number : 4840001
    • Morelos
      • Temixco, Morelos, Mexiko, 62587
        • Investigational Site Number : 4840002
      • Caguas, Portoriko, 00725
        • Investigational Site Number : 6300001
      • Ponce, Portoriko, 00716
        • Investigational Site Number : 6300003
      • Trujillo Alto, Portoriko, 00976
        • Investigational Site Number : 6300004
    • Alabama
      • Birmingham, Alabama, Spojené státy, 35205
        • Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400007
      • Grand Bay, Alabama, Spojené státy, 36541
        • South Alabama Medical Clinic- Site Number : 8400065
      • Mobile, Alabama, Spojené státy, 36608
        • MedPharmics - Mobile - Dauphin Street- Site Number : 8400017
    • Arkansas
      • Fayetteville, Arkansas, Spojené státy, 72703
        • Northwest Arkansas Pediatric Clinic- Site Number : 8400002
    • California
      • Bell Gardens, California, Spojené státy, 90201
        • Alliance Research Institute - Bell Gardens - Garfield Avenue- Site Number : 8400040
      • Huntington Park, California, Spojené státy, 90255
        • Matrix Clinical Research - Huntington Park- Site Number : 8400018
      • La Mesa, California, Spojené státy, 91942
        • Paradigm Clinical Research Centers- Site Number : 8400059
      • Los Angeles, California, Spojené státy, 90057
        • Matrix Clinical Research - Los Angeles- Site Number : 8400008
      • Oakland, California, Spojené státy, 94611
        • Kaiser Permanente - Oakland Medical Center- Site Number : 8400047
      • Palo Alto, California, Spojené státy, 94304
        • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400070
      • Roseville, California, Spojené státy, 95661
        • Kaiser Permanente - Sierra Gardens- Site Number : 8400063
      • Sacramento, California, Spojené státy, 95815
        • Kaiser Permanente - Point West Medical Offices- Site Number : 8400064
      • San Jose, California, Spojené státy, 95119
        • Kaiser Permanente - San Jose Medical Center- Site Number : 8400060
      • Santa Clara, California, Spojené státy, 95051
        • Kaiser Permanente - Santa Clara Medical Center- Site Number : 8400061
      • Sherman Oaks, California, Spojené státy, 91356-4173
        • Integrated Clinical Research LLC- Site Number : 8400036
      • Walnut Creek, California, Spojené státy, 94596
        • Kaiser Permanente - Walnut Creek Medical Center- Site Number : 8400062
    • District of Columbia
      • Washington D.C., District of Columbia, Spojené státy, 20016
        • Velocity Clinical Research - Washington DC- Site Number : 8400050
    • Florida
      • Doral, Florida, Spojené státy, 33166
        • Prohealth Research Center- Site Number : 8400068
      • Hollywood, Florida, Spojené státy, 33021
        • The Medici Medical Research- Site Number : 8400055
      • Miami, Florida, Spojené státy, 33126
        • Dade Research Center- Site Number : 8400014
      • Miami Lakes, Florida, Spojené státy, 33014
        • Riveldi Biomedical Research and Associates - Miami Lakes- Site Number : 8400015
      • Pensacola, Florida, Spojené státy, 32501
        • SEC Clinical Research - Pensacola- Site Number : 8400034
      • Tampa, Florida, Spojené státy, 33613
        • PAS Research- Site Number : 8400005
    • Idaho
      • Idaho Falls, Idaho, Spojené státy, 83404
        • Leavitt Women's Healthcare- Site Number : 8400009
    • Iowa
      • Sioux City, Iowa, Spojené státy, 51106
        • Velocity Clinical Research - Sioux City- Site Number : 8400054
    • Kansas
      • El Dorado, Kansas, Spojené státy, 67042
        • Alliance for Multispeciality Research - El Dorado- Site Number : 8400019
    • Kentucky
      • Lexington, Kentucky, Spojené státy, 40536
        • University of Kentucky Chandler Medical Center- Site Number : 8400051
    • Louisiana
      • New Orleans, Louisiana, Spojené státy, 70119
        • Velocity Clinical Research - New Orleans- Site Number : 8400058
      • New Orleans, Louisiana, Spojené státy, 70125
        • Research Works INC- Site Number : 8400044
    • Mississippi
      • Gulfport, Mississippi, Spojené státy, 39503
        • Velocity Clinical Research - Gulfport- Site Number : 8400011
    • Missouri
      • Springfield, Missouri, Spojené státy, 65802
        • QPS Bio-Kinetic Clinical Applications- Site Number : 8400046
    • Montana
      • Great Falls, Montana, Spojené státy, 59405
        • Boeson Research - Great Falls- Site Number : 8400041
      • Missoula, Montana, Spojené státy, 59804
        • Boeson Research - Missoula- Site Number : 8400006
    • Nebraska
      • Grand Island, Nebraska, Spojené státy, 68803
        • Velocity Clinical Research - Grand Island- Site Number : 8400016
      • Lincoln, Nebraska, Spojené státy, 68516
        • Midwest Childrens Health Research Institute- Site Number : 8400038
      • Omaha, Nebraska, Spojené státy, 68134
        • Velocity Clinical Research - Omaha- Site Number : 8400001
    • Nevada
      • Henderson, Nevada, Spojené státy, 89014
        • PAS Research - Henderson- Site Number : 8400049
    • New York
      • Garden City, New York, Spojené státy, 11530
        • NYU Langone Cardiothoracic Surgery Associates - Garden City- Site Number : 8400048
      • Liverpool, New York, Spojené státy, 13088
        • Summerwood Pediatrics- Site Number : 8400021
      • Syracuse, New York, Spojené státy, 13210
        • SUNY Upstate Medical University - Syracuse- Site Number : 8400029
    • Ohio
      • Dayton, Ohio, Spojené státy, 45414
        • Ohio Pediatrics - Dayton- Site Number : 8400033
      • Dayton, Ohio, Spojené státy, 45409
        • Dayton Clinical Research- Site Number : 8400030
      • South Euclid, Ohio, Spojené státy, 44121
        • Senders Pediatrics- Site Number : 8400022
    • Oregon
      • Gresham, Oregon, Spojené státy, 97030
        • Cyn3rgy Research- Site Number : 8400053
    • Pennsylvania
      • Erie, Pennsylvania, Spojené státy, 16506
        • Square-1 Clinical Research- Site Number : 8400031
      • Pittsburgh, Pennsylvania, Spojené státy, 15227
        • Pas Research - Pittsburgh- Site Number : 8400043
    • South Carolina
      • Charleston, South Carolina, Spojené státy, 29407
        • Neighbors Pediatrics- Site Number : 8400072
      • Greenville, South Carolina, Spojené státy, 29607
        • Tribe Clinical Research - Greenville - Verdae Boulevard- Site Number : 8400012
    • Texas
      • Corpus Christi, Texas, Spojené státy, 78413
        • South Texas Clinical Research- Site Number : 8400004
      • Dallas, Texas, Spojené státy, 75230
        • Javara - Privia Medical Group North Texas - Dallas- Site Number : 8400003
      • Edinburg, Texas, Spojené státy, 78539
        • PAS Research - Children's Care Clinic- Site Number : 8400035
      • Fort Worth, Texas, Spojené státy, 76104
        • Helios Clinical Research - Fort Worth - 8th Avenue- Site Number : 8400020
      • Houston, Texas, Spojené státy, 77008
        • Ventavia Research Group - Houston - North Loop West- Site Number : 8400010
      • Houston, Texas, Spojené státy, 77065
        • DM Clinical Research - Houston - Jones Road- Site Number : 8400052
      • Houston, Texas, Spojené státy, 77070
        • Mercury Clinical Research - Houston - Savoy Drive- Site Number : 8400045
      • Houston, Texas, Spojené státy, 77090
        • Houston Clinical Research Associates- Site Number : 8400013
      • Houston, Texas, Spojené státy, 77030
        • The University of Texas Health Science Center- Site Number : 8400037
      • Houston, Texas, Spojené státy, 77071
        • La Providence Pediatrics & Family Clinics- Site Number : 8400039
      • League City, Texas, Spojené státy, 77555
        • University of Texas Medical Branch at Galveston- Site Number : 8400057
      • League City, Texas, Spojené státy, 77573
        • Maximos Ob/Gyn- Site Number : 8400024
      • Plano, Texas, Spojené státy, 75093
        • Research Your Health- Site Number : 8400066
      • Richmond, Texas, Spojené státy, 77469
        • Pediatric Center - Richmond- Site Number : 8400032
      • Tomball, Texas, Spojené státy, 77375
        • North Houston Internal Medicine & Pediatric Clinic- Site Number : 8400025
    • Utah
      • Orem, Utah, Spojené státy, 84057
        • Utah Valley Pediatrics - Orem- Site Number : 8400067
      • Pleasant View, Utah, Spojené státy, 84404
        • Ogden Clinic - Mountain View - CCT Research- Site Number : 8400056
      • Roy, Utah, Spojené státy, 84067
        • Wee Care Pediatrics - Roy- Site Number : 8400071

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

6 měsíců až 1 rok (Dítě)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Aged 6 months for Cohort 1 and 12 months for Cohort 2 on the day of inclusion ("6 months" means from the day of the 6-month birthday to the day before the 7-month birthday and "12 months" means from the day of the 12-month birthday to the day before the 13-month birthday)
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • For Cohort 1: Infant received doses of vaccines containing hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type B (Hib), and inactivated poliovirus vaccine (IPV) antigens, with Advisory Committee on Immunization Practice (ACIP) recommended vaccines. The last dose(s) of these vaccines must be at least 28 days before the first study visit
  • Infant received the recommended doses of a recommended pneumococcal conjugate vaccine (as per local schedule) at least 28 days before the first study visit.

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known previous infection with diphtheria, tetanus, Hib, measles, mumps, rubella, rotavirus, pneumococcus, polio, hepatitis B virus
  • Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • History of medically diagnosed wheezing
  • Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Probable or confirmed ongoing case of viral respiratory infection (including COVID 19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.
  • Member of a household that contains an immunocompromised individual, including, but not limited to:
  • A person living with human immunodeficiency virus (HIV)
  • A person who has received chemotherapy within the 12 months prior to study enrollment
  • A person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
  • A person living with a solid organ or bone marrow transplant
  • Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion
  • History of definitive contraindications to any of the concomitant vaccines that will be administered as part of the study protocol
  • Participant's biological mother with previous receipt or planned administration of an investigational RSV vaccine during pregnancy and/or breastfeeding
  • Receipt of any vaccine in the 4 weeks preceding RSVt vaccine administration or planned receipt of any vaccine outside of study protocol in the 4 weeks following RSVt vaccine administration, except for influenza and/or COVID-19 vaccination, which may be received at least 1 week before or 1 week after RSVt vaccine administration
  • Previous receipt of an investigational RSV vaccine or receiving any anti RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
  • Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration or planned receipt for duration of the study
  • For Cohort 1: Prior receipt of routine 6-month pediatric vaccine doses (as per local schedule)
  • For Cohort 2: Prior receipt of routine 12-month pediatric vaccine doses (as per local schedule)
  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Prevence
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Ostatní jména:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • Vaxelis®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • Pentacel®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • RECOMBIVAX HB® nebo alternativní monovalentní vakcína proti hepatitidě B

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • PREVNAR 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

Ostatní jména:
  • RotaTeq®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Experimentální: Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Ostatní jména:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • Vaxelis®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • Pentacel®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • RECOMBIVAX HB® nebo alternativní monovalentní vakcína proti hepatitidě B

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • PREVNAR 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

Ostatní jména:
  • RotaTeq®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Experimentální: Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Ostatní jména:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • PREVNAR 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

Ostatní jména:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

Ostatní jména:
  • VARIVAX®
Experimentální: Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Ostatní jména:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Ostatní jména:
  • PREVNAR 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

Ostatní jména:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

Ostatní jména:
  • VARIVAX®

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
RSV A serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
Časové okno: Day 85

Antibody titers at Day 85

Day 85
RSV B serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
Časové okno: Day 85

Antibody titers at Day 85

Day 85
RSV A serum neutralizing antibody titers at Day 113 Groups 2 and 4
Časové okno: Day 113

Antibody titers at Day 113

Day 113
RSV B serum neutralizing antibody titers at Day 113 Groups 2 and 4
Časové okno: Day 113

Antibody titers at Day 113

Day 113

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Anti- hepatitis B surface antigen (HBsAg) Immunoglobulin g (IgG) antibody (A)b concentrations ≥ 10 milli international units per milliliter (mIU/mL) Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti- polyribosylribitol phosphate (PRP) Ab concentrations ≥ 0.15 micrograms per milliliter (µg/mL) Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-poliovirus types (1, 2, and 3) Ab titers ≥ 1:8 Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pertussis Ab concentrations pertussis toxin, filamentous hemagglutinin , pertactin, fimbriae (PT, FHA, PRN, FIM) Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-diphtheria Ab concentrations ≥ 0.1 IU/mL Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-tetanus Ab concentrations ≥ 0.1 IU/mL Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by electrochemiluminescence (ECL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-measles Ab concentrations ≥ 255 mIU/mL Cohort 2
Časové okno: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-mumps Ab concentrations ≥ 10 antibody units (AbU/mL) Cohort 2
Časové okno: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-rubella Ab concentrations ≥ 10 IU/mL Cohort 2
Časové okno: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) units/mL Cohort 2
Časové okno: 28 days after the 12 month routine vaccinations

Antibody 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by ECL Cohort 2
Časové okno: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-PRP Ab concentrations (µg/mL) Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations (IU/mL) Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations ≥ 0.01 IU/mL Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations (IU/mL) Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations ≥ 0.01 IU/mL Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations (mIU/mL) Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations ≥ 100 mIU/mL Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-poliovirus types (1, 2, and 3) Ab titers Cohort 1
Časové okno: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-measles Ab concentrations (mIU/mL) Cohort 2
Časové okno: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-mumps Ab concentrations (AbU/mL) Cohort 2
Časové okno: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-rubella Ab concentrations (IU/mL) Cohort 2
Časové okno: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-varicella Ab concentrations (gpELISA units/mL)
Časové okno: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
RSV A serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
Časové okno: Day 1

Antibody titers at Day 1

Day 1
RSV B serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
Časové okno: Day 1

Antibody titers at Day 1

Day 1
RSV A serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 1 Cohort 1 and Cohort 2
Časové okno: 28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
RSV B serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 Cohort 1 and Cohort 2
Časové okno: 28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
Presence of solicited administration site reactions within 21 days after each investigational medicinal product (IMP) administration Cohort 1 and Cohort 2
Časové okno: 21 days after each IMP administration

Number of participants experiencing solicited administration site reactions

21 days after each IMP administration
Presence of solicited systemic reactions within 21 days after each IMP administration Cohort 1 and Cohort 2
Časové okno: 21 days after each IMP administration

Number of participants experiencing solicited systemic site reactions

21 days after each IMP administration
Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each study intervention administration Cohort 1 and Cohort 2
Časové okno: Within 30 minutes after each study intervention administration

Number of participants experiencing unsolicited systemic adverse events

Within 30 minutes after each study intervention administration
Presence of unsolicited AEs within 28 days after each study intervention administration Cohort 1 and Cohort 2
Časové okno: Within 28 days after each study intervention administration

Number of participants experiencing unsolicited AEs

Within 28 days after each study intervention administration
Presence of medically attended adverse events (MAAEs) throughout the study Cohort 1 and Cohort 2
Časové okno: Throughout the study, approximately 9 months

Number of participants experiencing MAAEs

Throughout the study, approximately 9 months
Presence of serious adverse events (SAEs) throughout the study Cohort 1 and Cohort 2
Časové okno: Throughout the study, approximately 9 months

Number of participants experiencing SAEs

Throughout the study, approximately 9 months
Presence of adverse events of special interest (AESIs) throughout the study Cohort 1 and Cohort 2
Časové okno: Throughout the study, approximately 9 months

Number of participants experiencing AESIs

Throughout the study, approximately 9 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

13. května 2024

Primární dokončení (Aktuální)

18. září 2025

Dokončení studie (Aktuální)

18. září 2025

Termíny zápisu do studia

První předloženo

29. dubna 2024

První předloženo, které splnilo kritéria kontroly kvality

29. dubna 2024

První zveřejněno (Aktuální)

3. května 2024

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

5. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

15. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • VAD00016
  • VAD00016 (Jiný identifikátor: Sanofi Identifier)
  • U1111-1290-7356 (Identifikátor registru: ICTRP)
  • 2024-000262-15 (Číslo EudraCT)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .